”There’s more money than there has been in years”
The recently held J.P. Morgan Health Care Conference was characterized by an almost euphoric atmosphere and free-flowing risk capital, according to Dansk Biotek’s Martin Bonde. Venture groups are feeling the increased competition for good deals, he says.
BY BENJAMIN WERNER CHRISTENSEN & STEFAN SINGH KAILAY
There are more money available to up-and-coming biotech companies than there has been in years, Martin Bonde, Chairman of the industry organization Dansk Biotek, says in an interview with MedWatch following the recently held J.P. Morgan Health Care Conference in San Francisco.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Danish life science passes on opportunity in NY
For abonnenter
Drusebjerg: The beginning of a bubble
For abonnenter
Biotech Chairman: You pay for the network
For abonnenter
